IL6 and neoplasm: Among others, LRG1 has been found to drive IL-6-dependent pathological angiogenesis through the STAT3 signaling pathway (26, 27), destabilize tumor vasculature and promote tumor growth and metastasis (28–32), drive chronic kidney and lung disease (33–40), stimulate fibrosis (33, 34, 41–48), contribute to diabetes-related pathology (17, 49–57), and regulate pathological placental angiogenesis (58).